Evidence map›Paper›PMID 41613561›Full record

ReviewFrontiers in oncology2025

Progress and prospects of organoids in the pathogenesis of lung cancer and screening of antitumor drugs.

Yiqiong Li, Yuanjie Shang, Na Zhang, Jiarui Li, Zijiang Yang

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yiqiong Li *Medical College, Henan University of Chinese Medicine, Zhengzhou, China.
Yuanjie Shang *Medical College, Henan University of Chinese Medicine, Zhengzhou, China.
Na ZhangMedical College, Henan University of Chinese Medicine, Zhengzhou, China.
Jiarui LiMedical College, Henan University of Chinese Medicine, Zhengzhou, China.
Zijiang YangMedical College, Henan University of Chinese Medicine, Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer, a major global public health issue for decades, is characterized by high incidence and mortality rates. Over the past twenty years, numerous novel therapies have emerged. However, due to the substantial genetic and phenotypic heterogeneity among patients, current treatment modalities still yield low cure rates for advanced lung cancer, creating an urgent need to develop precision medicine aided by personalized tumor models. The rise and advancement of three-dimensional organoid culture technology have brought new hope to this endeavor. Patient-derived organoids can closely mimic the

Indexed as

antitumor drug screenslung cancerorganoidspathogenesisprecision medicine

Identifiers

PMID41613561
PMCPMC12846966

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.